|
07 Mar 2022 |
Targeted Protein Degradation (TPD) by proteasomal PROTACs & molecular glues, lysosomal LYTACs and autophagic AUTOTACs or ATTECs provides plenty of opportunities to drug undruggable targets
|
|
06 Oct 2021 |
Prodrug antibodies and cytokines generated by masking technologies provide plenty of opportunities for founders, investors and partnerships
|
|
01 Jul 2021 |
Vectorized Antibodies for In Vivo Expression by DNA and mRNA: an emerging new technology
|
|
11 Jun 2019 |
New report about bispecific antibodies engaging T-cells and NK cells
|
|
23 May 2018 |
TCR Engineered T-Cells 2018: coming out of the shadow to the light
|
|
12 Mar 2018 |
All time high of biologics sales in 2017 driven by cancer antibodies and innovative anti-inflammatory antibodies
|
|
25 Jan 2018 |
Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-permeating biologics
|
|
23 Jun 2017 |
mRNA Vaccines and Therapeutics: are you ready to be on the ground floor of the next big new therapeutic modality?
|
|
17 Mar 2017 |
2016 was another record year of biologics sales with antibodies accounting for two-thirds
|
|
25 Jan 2017 |
Oncolytic Viruses: a still undervalued technology with strong growth perspectives
|
|
19 Dec 2016 |
More than ever antibody-drug conjugates generated by new technologies are undergoing clinical proof-of-concept testing
|
|
09 Dec 2016 |
Complimentary copy of report „Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins“
|
|
10 Aug 2016 |
Beyond anti-CD19 CARTs: the future of CAR T-cells depends on the convergence of technologies
|
|
29 May 2016 |
Increasing impact of biosimilars on the market of originator therapeutic antibodies
|
|
13 May 2016 |
Improved next generation of T-cell redirecting bispecific antibodies enters clinical proof-of-concept phase
|
|
13 Mar 2016 |
Biologics sales in 2015 exceeded the USD 150 bln threshold
|
|
04 Feb 2016 |
RORgamma, a hot target for treatment of Th17 cell-mediated immune diseases, but also for immune therapy of cancer
|
|
02 Dec 2015 |
Antibody-drug conjugate technology on the path to productivity providing plenty of opportunities
|
|
18 Mar 2015 |
Innovation with therapeutic antibodies drives 2014 sales of recombinant biologics
|
|
12 Mar 2015 |
Engineered T-Cell Receptor and T-Cells: independent, but also complementary tools for immuno-oncology with great prospects
|
|
29 Dec 2014 |
Recombinant coagulation factors: market, products, R&D pipeline and new competition from alternative procoagulants and gene & cell therapy
|
|
16 Jul 2014 |
Botulinum Neurotoxins: opportunities for biosimilars and biosuperiors to capture market shares (2)
|
|
09 May 2014 |
Recombinant therapeutic antibodies consolidate as growth driver of biologics sales in 2013
|
|
23 Jan 2014 |
The exponential growth of the field of antibody-drug conjugates provides plenty of business opportunities
|
|
30 Jun 2013 |
Redistribution of market shares in the hemophilia market of recombinant coagulation factors due to new approvals and differential profiles
|
